Abstract
Background/Objectives: Cyclodextrin inclusion complexation is widely used to improve the dissolution of poorly water-soluble drugs, but its effects on the manufacturability and quality of orally disintegrating tablets (ODTs) remain insufficiently understood. This study investigated how β-cyclodextrin (β-CD) and hydroxypropyl-β-cyclodextrin (HP-beta-CD) inclusion complexes affect the powder properties, tablet quality attributes, and dissolution performance of flurbiprofen ODTs.
Methods: Flurbiprofen inclusion complexes with beta-CD and HP-beta-CD were prepared by freeze-drying and characterized using scanning electron microscopy (SEM), Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and X-ray diffraction (XRD). ODTs containing pure flurbiprofen, inclusion complexes, or corresponding physical mixtures were manufactured by direct compression. Powder flowability and compressibility were assessed using the Hausner ratio and Carr’s index. Tablets were evaluated for weight variation, content uniformity, hardness, friability, disintegration, and dissolution at pH 1.2, 4.5, and 6.8.
Results: Physicochemical characterization studies confirmed successful inclusion complex formation. β-CD formulations exhibited poorer flowability and compressibility than HP-beta-CD formulations and pure drug blends. All ODTs complied with pharmacopeial requirements for weight variation and content uniformity. Inclusion complex-based tablets showed lower hardness and higher friability, whereas physical mixture-based tablets demonstrated greater mechanical strength. HP-beta-CD inclusion complexes enhanced dissolution at pH 1.2 and 4.5. At pH 6.8, all formulations released more than 95% of flurbiprofen within 30 min.
Conclusions: Cyclodextrin complexation influenced both the quality attributes and dissolution performance of flurbiprofen ODTs, highlighting the importance of cyclodextrin selection during formulation development.
Introduction
Orally disintegrating tablets (ODTs) have attracted considerable interest in pharmaceutical development owing to their ability to rapidly disintegrate in the oral cavity. Unlike conventional tablets, which are generally swallowed intact with water and subsequently disintegrate in the gastrointestinal tract, ODTs are designed to disintegrate rapidly upon contact with saliva, allowing administration without the need for water or swallowing an intact tablet. This characteristic enhances patient compliance, particularly among individuals with swallowing difficulties, including paediatric and geriatric populations and individuals with neurological disorders such as Parkinson’s disease and amyotrophic lateral sclerosis, in which dysphagia is a common complication [1,2,3].
An important consideration in the formulation of orally disintegrating tablets (ODTs) is tasting perception, as making the inherent bitterness of certain drug substances remains a significant challenge. Effective taste-masking strategies are therefore essential to improve patient acceptability and adherence to treatment [4,5]. In recent years, the complexation of drug molecules with cyclodextrins (CDs) has attracted considerable attention due to its potential to enhance the solubility, stability, and bioavailability of poorly water-soluble drugs while reducing their perceived bitterness through the formation of inclusion complexes [6,7,8]. Accordingly, several studies have reported the development of ODT formulations incorporating drug–CD inclusion complexes [8,9,10,11]. Despite these advantages, the incorporation of CD inclusion complexes into solid dosage forms may present technological challenges, particularly regarding powder flow and tableting performance [12,13]. Changes in powder characteristics associated with complex formation may affect the manufacturing process and subsequently influence critical tablet quality attributes, including hardness, friability, and disintegration time. Therefore, understanding the effects of CD complexation on powder properties and tablet performance is essential for the successful development of ODT formulations.
In this context, the preparation and physicochemical characterization of flurbiprofen–beta-cyclodextrin (beta-CD) and hydroxypropyl-beta-cyclodextrin (HP-beta-CD) inclusion complexes have been investigated in previous studies [14]. Beyond these physicochemical characterizations, Cirri et al. [15] investigated the complexation of flurbiprofen with beta-cyclodextrin (beta-CD), methyl-beta-cyclodextrin (M-beta-CD), and hydroxyethyl-beta-cyclodextrin (HE-β-CD) using different preparation techniques and subsequently developed fast-dissolving tablets containing selected flurbiprofen–CD systems. Specifically, co-lyophilized flurbiprofen–β-CD and kneaded flurbiprofen–M-beta-CD complexes were incorporated into tablet formulations containing different combinations of excipients, including chitosan and/or spray-dried lactose. The resulting tablets were evaluated in terms of weight uniformity, friability, disintegration time, and dissolution performance, with particular emphasis on achieving rapid drug dissolution. Although this study demonstrated the feasibility of developing fast-dissolving tablets containing flurbiprofen–CD complexes, it did not systematically compare the effects of CD type and complexation state on powder properties and tablet quality attributes under identical formulation and manufacturing conditions.
Flurbiprofen is a poorly water-soluble, lipophilic drug characterized by a log p value of approximately 3.99, an aqueous solubility of approximately 0.01 mg/mL at 25 °C, and a pKa of approximately 4.6, resulting in pH-dependent solubility. It is therefore classified as a Biopharmaceutics Classification System (BCS) Class II drug, exhibiting low solubility and high permeability [16,17,18,19]. These physicochemical characteristics make flurbiprofen a suitable model drug for investigating CD-based formulation strategies. Although CD complexation has been widely investigated as a means of improving the dissolution characteristics of poorly water-soluble drugs, its influence on powder properties and the manufacturability of ODTs requires further consideration, particularly when comparing physical mixtures and inclusion complexes prepared using different CD derivatives.
Accordingly, the present study aimed to systematically investigate the influence of CD type and inclusion-complex formation on the powder properties, tableting performance, and critical quality attributes of flurbiprofen-containing ODTs. Particular emphasis was placed on the direct comparison of formulations containing flurbiprofen/β-CD and flurbiprofen/HP-beta-CD inclusion complexes with their corresponding physical mixtures and a flurbiprofen-only control formulation under identical formulation and manufacturing conditions. By adopting this comparative approach, the study sought to distinguish the effects associated with CD type and complexation state and to provide a better understanding of their implications for ODT manufacturability and compliance with relevant pharmacopeial quality requirements.
Download the full article as PDF here Impact of beta-Cyclodextrin and Hydroxypropyl-𝛃-Cyclodextrin Inclusion Complexes on Quality Attributes of Flurbiprofen Orally Disintegrating Tablets
or continue reading here
Materials
Flurbiprofen was supplied by Hetero Drugs Ltd. (Hyderabad, India). Ludipress® and Kollidon® CL (crospovidone) were obtained from BASF (Ludwigshafen am Rhein, Germany). Avicel® PH-102 (microcrystalline cellulose) was provided by DFE Pharma (Goch, Germany). Beta-Cyclodextrin (beta-CD) and hydroxypropyl-beta-cyclodextrin (HP-beta-CD) were purchased from Thermo Scientific (Waltham, MA, USA). Magnesium stearate and talc were supplied by Sigma-Aldrich (St. Louis, MO, USA). All other chemicals used were of analytical grade.
Alakrami, N.; Kahraman, E. Impact of β-Cyclodextrin and Hydroxypropyl-β-Cyclodextrin Inclusion Complexes on Quality Attributes of Flurbiprofen Orally Disintegrating Tablets. Pharmaceuticals 2026, 19, 1724. https://doi.org/10.3390/ph19111724
Are you looking for excipients in commercial quantities?












































All4Nutra







